A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.02.021
Full Text
Open PDFAbstract
Available in full text
Date
July 1, 2015
Authors
Publisher
Elsevier BV